PositiveSingles.com - the best, most trusted and largest anonymous STD dating site!

Herpes Survival Kit - a specially designed pack containing everything you need to combat herpes and cold sore outbreaks (at a minimum cost to your wallet).

only search Racoon.com

"The Good News about the Bad News - 
Herpes: Everything You Need to Know
"  
Terri Warren's new book - which we do endorse.

First time visitor? Please Learn about Registering and read our policy page.
{Home}{Awareness}{Research}{Treatment}{HHP FAQ}{Bookstore}{Bio/Info Page}

The Original Herpes Home Page Discussion Forums

Subject: "Genocea - animal studies progress - HSV2 therapeutic vaccine"     Previous Topic | Next Topic
Printer-friendly copy     Email this topic to a friend    
Conferences Herpes News Topic #1572
Reading Topic #1572
muffinadmin
Member since Sep-10-04
6230 posts
Aug-05-12, 08:52 PM (CST)
Click to EMail muffin Click to send private message to muffin Click to view user profileClick to add this user to your buddy list  
"Genocea - animal studies progress - HSV2 therapeutic vaccine"
 
http://www.businesswire.com/news/home/20120805005014/en/Genocea-Unveils-Protective-Therapeutic-Vaccine-Herpes-Simplex

EXCERPT

Genocea Unveils Protective Therapeutic Vaccine for Herpes Simplex Virus Type 2 (HSV-2)

Candidate vaccine reduced duration and severity of symptoms in preclinical models
Data validate T cell vaccine strategy for Herpes Simplex Virus type 2 (HSV-2)
Data will be presented this week at 37th Annual International Herpesvirus Workshop
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genocea Biosciences announced today the presentation of new data supporting its novel approach to developing a first-in-class, protein subunit therapeutic vaccine for Herpes Simplex Virus type 2 (HSV-2). The data, to be presented this week at the 37th annual International Herpesvirus Workshop (IHW) in Calgary, Alberta, highlight antigens identified through Genocea’s unique technology platform that stimulate T cell immune responses to HSV-2. A candidate vaccine consisting of these antigens reduced viral shedding and clinical disease when tested in a preclinical model of HSV-2 infection.

“As we advance toward the clinic, these data give us great confidence in our lead vaccine candidate, and suggest that we have identified full protein antigens that stimulate a balanced and effective B and T cell immune response.”
“We are highly encouraged by these data, which mark the first time a protein subunit therapeutic vaccine has been shown to affect disease and viral shedding significantly in this model,” said Jessica Flechtner, Ph.D., Vice President, Research, Genocea Biosciences. “As we advance toward the clinic, these data give us great confidence in our lead vaccine candidate, and suggest that we have identified full protein antigens that stimulate a balanced and effective B and T cell immune response.”

In one of two studies presented, Genocea researchers studied the T cell immune responses to each HSV-2 protein among patients with HSV-2 infection or exposure. Using ATLAS™, Genocea’s proprietary high-throughput screening platform, they identified HSV-2 proteins (or antigens) associated with protective immune responses in volunteers who had no evidence of infection but had been exposed to HSV-2, or who had relatively mild HSV-2 infections. Patients with severe disease, as indicated by multiple outbreaks of genital herpes, had weaker or no responses to these same proteins.

Genocea advanced one antigen, ICP4, and evaluated its therapeutic effectiveness when formulated as a vaccine with glycoprotein D in subsequent studies. In a therapeutic efficacy model, vaccinated guinea pigs showed a 45 percent reduction in duration, and a 55 percent reduction in severity, of clinical symptoms. Furthermore, no measurable virus was found in the reproductive tract of the vaccinated animals after completion of the immunization course.


  Alert | IP Printer-friendly page | Edit | Reply | Reply With Quote | Top
Koolmom2008
Member since Apr-11-12
62 posts
Aug-18-12, 04:20 PM (CST)
Click to EMail Koolmom2008 Click to send private message to Koolmom2008 Click to view user profileClick to add this user to your buddy list  
1. "RE: Genocea - animal studies progress - HSV2 therapeutic vaccine"
In response to message #0
 
   LAST EDITED ON Aug-18-12 AT 04:23 PM (CDST)
 
Thanks Muffin for posting.

I looked on their website they posted another "News" since 08/15/2012

http://www.businesswire.com/news/home/20120815005187/en/Genocea-Initiates-Phase-12a-Study-Therapeutic-Vaccine

August 15, 2012 07:30 AM Eastern Daylight Time
Genocea Initiates a Phase 1/2a Study with Its Therapeutic Vaccine Candidate for Herpes Simplex Virus-2 (HSV-2)



  Alert | IP Printer-friendly page | Edit | Reply | Reply With Quote | Top
muffinadmin
Member since Sep-10-04
6230 posts
Aug-19-12, 02:09 PM (CST)
Click to EMail muffin Click to send private message to muffin Click to view user profileClick to add this user to your buddy list  
2. "RE: Genocea - animal studies progress - HSV2 therapeutic vaccine"
In response to message #1
 
LAST EDITED ON Aug-19-12 AT 02:09 PM (CDST)
 
And they are recruiting human volunteers for their study...

http://clinicaltrials.gov/ct2/show/NCT01667341?term=genocea&rank=1


Alabama
Indiana
Ohio
Oregon
Texas
Washington State


  Alert | IP Printer-friendly page | Edit | Reply | Reply With Quote | Top

Conferences | Topics | Previous Topic | Next Topic

 

Advertisements appearing on this page do not constitute any endorsement of 
those products or services by HHP or its management.

All opinions expressed here by the HHP, its management and participants constitute just that, opinions.
No medical relationship with any participant is implied in any way.
Each individual's personal doctor is responsible for the medical advice and care of that person.